HC Wainwright Reduces Earnings Estimates for GH Research

GH Research PLC (NASDAQ:GHRS) – Equities researchers at HC Wainwright lowered their FY2024 earnings estimates for GH Research in a research note issued to investors on Tuesday, November 19th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.76) per share for the year, down from their previous forecast of ($0.75). HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.78) per share. HC Wainwright also issued estimates for GH Research’s Q1 2025 earnings at ($0.22) EPS, Q3 2025 earnings at $0.22 EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.88) EPS, FY2026 earnings at ($1.10) EPS and FY2027 earnings at ($1.18) EPS.

A number of other equities analysts have also recently issued reports on GHRS. JMP Securities reaffirmed a “market outperform” rating and issued a $39.00 price objective on shares of GH Research in a research note on Wednesday, September 4th. Canaccord Genuity Group reduced their price objective on shares of GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a research note on Monday, November 18th.

GH Research Stock Performance

Shares of GHRS stock opened at $9.27 on Friday. GH Research has a 52-week low of $5.05 and a 52-week high of $14.99. The stock has a market cap of $482.32 million, a PE ratio of -11.73 and a beta of 0.74. The firm’s 50 day moving average price is $7.91 and its two-hundred day moving average price is $10.31.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.03.

Institutional Investors Weigh In On GH Research

An institutional investor recently raised its position in GH Research stock. Lynx1 Capital Management LP boosted its holdings in GH Research PLC (NASDAQ:GHRS) by 80.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,310,563 shares of the company’s stock after purchasing an additional 1,471,946 shares during the period. GH Research comprises about 9.1% of Lynx1 Capital Management LP’s portfolio, making the stock its 6th largest holding. Lynx1 Capital Management LP owned 6.36% of GH Research worth $35,291,000 at the end of the most recent quarter. 56.90% of the stock is currently owned by institutional investors and hedge funds.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).